Home
Anal Cancer
Biliary Tract Cancer
Bladder Cancer
Brain Tumor
Breast Cancer
Cancer of Unknown Primary
Carcinoid Tumor
Cervical Cancer
Colorectal Cancer
Endometrial Cancer
Esophageal Cancer
Gastric Cancer
Gastrointestinal Stromal Tumor
Head and Neck Cancer
Hepatocellular Cancer
Kaposi Sarcoma
Leukemia
Lung Cancer
Lymphoma
Melanoma
Mesothelioma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Renal Cell Cancer
Sarcoma
Testicular Cancer
Thymoma
Myelodysplastic Syndrome
Dosage for Hepatic Dysfunction
Dosage for Renal Dysfunction
Calculation of Carboplatin Dose
Biliary Tract Cancer



Gemcitabine
Gemcitabine (Gemzar) 1000 mg/m2 iv d1, 8
Q3w

Park, JS et al. Single-agent Gemcitabine in the Treatment of Advanced Biliary Tract Cancers: a Phase II Study. Jpn J Clin Oncol 2005; 35:68 (link to the article).

Docetaxel
Docetaxel (Taxotere) 100 mg/m2 iv
Q3w

Papakostas, P et al. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. Eur J Cancer 2001; 37:1833 (link to the article)
.
Gemcitabine + Capecitabine
Gemcitabine (Gemzar) 1000 mg/m2 iv d1, 8
Capecitabine (Xeloda) 650 mg/m2 po bid d1-14
Q3w

Koeberle D et al. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2008; 26:3702 (link to the article).

Knox, JJ et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005; 23:2332 (link to the article).

Gemcitabine + Cisplatin
Gemcitabine (Gemzar) 1250 mg/m2 iv d1, 8
Cisplatin (CDDP) 75 mg/m2 iv d1
Q3w

Thongprasert S et al. Phase II study of gemcitabine and cisplatin as first line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005; 16:279 (link to the article).

Gemcitabine + Oxaliplatin
Gemcitabine (Gemzar) 1000 mg/m2 iv d1
Oxaliplatin (Eloxatin) 100 mg/m2 iv d2
Q2w

Andre, T et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15:1339 (link to the article)
.
5-FU + Cisplatin
5-FU 1000 mg/m2/d civi d1-5
Cisplatin (CDDP) 100 mg/m2 iv d2
Q3w

Ducreux, M et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 1998; 9:653 (link to the article)
.
LV5FU-P
Leucovorin 200 mg/m2 iv over 2 hrs d1
5-FU 400 mg/m2 iv bolus, followed by 600 mg/m2 iv over 22 hrs, d1 and 2
Cisplatin (CDDP) 50 mg/m2 iv d2
Q2w

Taieb, J et al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol 2002; 13:1192 (link to the article)

Erlotinib
Erlotinib (Tarceva) 150 mg po qd

Philip PA et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006; 24:3069 (link to the article).